Lexaria Biosciences

Lexaria Bioscience Granted First European Patent for DehydraTECH Technology

Lexaria Bioscience Corp. announced that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.

Molecule Signs Agreement with Hill Street Beverage Company Inc. to Produce Cannabis Infused Beverages

OTTAWA, ON, Oct. 15, 2020 /CNW/ – Molecule Holdings Inc. (CSE: MLCL) (“Molecule” or the “Company“), a Canadian craft-focused cannabis beverage production company, is pleased to announce that it has signed a term sheet with Hill Street Beverage Company Inc. (“Hill Street” or the “Company“) (TSXV: BEER) to produce select cannabis infused beverages for Hill Avenue Cannabis Co., aContinue reading “Molecule Signs Agreement with Hill Street Beverage Company Inc. to Produce Cannabis Infused Beverages”

Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Complements previously published data that cites Lexaria’s TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announced that it has received ethics board approval by a European university research hospital to conduct an exploratory clinical studyContinue reading “Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction”